ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer

Mayo Clinic60 enrolled

Overview

Researchers have developed a new test to measure a protein QSOX1 that is found to be elevated in subjects with pancreas cancer. Researchers are looking to use this test to compare subjects with pancreas cancer and subjects without pancreas cancer to see if this test could be used to diagnosis pancreas cancer.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Pancreas Cancer Pancreas Cyst

Interventions

Lateral Flow Assay (LFA)OTHER

Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein

Eligibility

Sex: ALLMin age: 17 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients with biopsy-proven adenocarcinoma prior to receiving any therapy such as surgery, radiation or chemotherapy. * Patients without pancreas cancer. * Adult patients with benign pancreas disorders such as pancreatitis with imaging within 12 months (CT, MRI, EUS) documenting no cancer. * Healthy adults with blood specimens in an existing biobank. * Patients with pancreatic cystic lesions. * Adult patients undergoing clinically indicated EUS-guided FNA biopsy of pancreatic cystic lesions. Exclusion Criteria: * Prior treatment for pancreas cancer. * Unable or unwilling to give consent.

Locations (1)

Mayo Clinic in Arizona

Scottsdale, Arizona, United States

Outcomes

Primary Outcomes

Quiescin Sulfhydryl Oxidase 1 (QSOX1) in the blood

Number of subjects with the presence and concentration of QSOX1 peptide found in the blood samples by the lateral flow assay (LFA) test

Time frame: Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.